Cargando…

Treatment algorithm in patients with ovarian cancer

Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergote, I, Denys, H, De Greve, J, Gennigens, C, Van De Vijver, K, Kerger, J, Vuylsteke, P, Baurain, JF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universa Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/
https://www.ncbi.nlm.nih.gov/pubmed/33123697
_version_ 1783598752968212480
author Vergote, I
Denys, H
De Greve, J
Gennigens, C
Van De Vijver, K
Kerger, J
Vuylsteke, P
Baurain, JF
author_facet Vergote, I
Denys, H
De Greve, J
Gennigens, C
Van De Vijver, K
Kerger, J
Vuylsteke, P
Baurain, JF
author_sort Vergote, I
collection PubMed
description Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.
format Online
Article
Text
id pubmed-7580261
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Universa Press
record_format MEDLINE/PubMed
spelling pubmed-75802612020-10-28 Treatment algorithm in patients with ovarian cancer Vergote, I Denys, H De Greve, J Gennigens, C Van De Vijver, K Kerger, J Vuylsteke, P Baurain, JF Facts Views Vis Obgyn Viewpoint Paper Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium. Universa Press 2020-10-08 /pmc/articles/PMC7580261/ /pubmed/33123697 Text en Copyright © 2020 Facts, Views & Vision http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Viewpoint Paper
Vergote, I
Denys, H
De Greve, J
Gennigens, C
Van De Vijver, K
Kerger, J
Vuylsteke, P
Baurain, JF
Treatment algorithm in patients with ovarian cancer
title Treatment algorithm in patients with ovarian cancer
title_full Treatment algorithm in patients with ovarian cancer
title_fullStr Treatment algorithm in patients with ovarian cancer
title_full_unstemmed Treatment algorithm in patients with ovarian cancer
title_short Treatment algorithm in patients with ovarian cancer
title_sort treatment algorithm in patients with ovarian cancer
topic Viewpoint Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/
https://www.ncbi.nlm.nih.gov/pubmed/33123697
work_keys_str_mv AT vergotei treatmentalgorithminpatientswithovariancancer
AT denysh treatmentalgorithminpatientswithovariancancer
AT degrevej treatmentalgorithminpatientswithovariancancer
AT gennigensc treatmentalgorithminpatientswithovariancancer
AT vandevijverk treatmentalgorithminpatientswithovariancancer
AT kergerj treatmentalgorithminpatientswithovariancancer
AT vuylstekep treatmentalgorithminpatientswithovariancancer
AT baurainjf treatmentalgorithminpatientswithovariancancer